Urodynamix Technologies Ltd. Announces Cross of 1,480,000 Common Shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of
1,480,000 common shares has been effected through Canaccord Capital Inc. at a
sales price of $0.05 per common share. The traded shares were sold by Barry
Allen, President and CEO of Urodynamix Technologies Ltd. who also purchased
2,782,450 common shares at a price of $0.05 per common share through the $1.5
million non-brokered private placement for 30,000,000 common shares that closed
on September 25, 2009. All of the shares issued by the Company pursuant to the
non-brokered private placement are subject to a 4-month resale restriction and
the Company will pay a commission of up to 7.5% on sales of common shares to
third parties.


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, erectile dysfunction, prostate
cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal
pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough
medical technology has the potential to beneficially affect more than 200
million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.